# Carlos Barrios

Source: https://onco.cc/people/barrios-carlos/  
OnCo record `barrios-carlos` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Carlos Barrios is the most visible Latin American voice in global breast cancer trials and a founder of the region's cooperative group LACOG.

## Summary

Carlos Barrios is a medical oncologist and Director of the Oncology Research Center at Hospital São Lucas PUCRS, a co-founder of the Latin American Cooperative Oncology Group (LACOG), and a collaborator with Hospital Israelita Albert Einstein and other major São Paulo centres. He has served on the steering committees of numerous global breast cancer trials and is the most visible Latin American voice in that field, having built LACOG to expand trial access across the region. His publications include analyses of trastuzumab emtansine in HER2-positive advanced breast cancer from the KAMILLA safety trial and a qualitative study of barriers to multidisciplinary breast cancer care in five Latin American countries. His interests are breast cancer, Latin American trials and global oncology.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical oncologist; Director, Oncology Research Center, Hospital São Lucas PUCRS; Latin American Cooperative Oncology Group
- Specialisms: Breast cancer; Clinical trials in Latin America; Global oncology

## Sources

- LACOG: https://lacog.org.br
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Barrios%20CH%5BAuthor%5D%20breast%20cancer%20Latin%20America

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- institutions: [Agência Nacional de Vigilância Sanitária](https://onco.cc/institutions/anvisa/), [Hospital de Clínicas de Porto Alegre](https://onco.cc/institutions/hcpa-porto-alegre/), [Hospital Israelita Albert Einstein](https://onco.cc/institutions/einstein-sao-paulo/)
- ideas: [Burden-matched funding for trials led in low- and middle-income countries](https://onco.cc/ideas/idea-fund-lmic-burden-match/), [Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded](https://onco.cc/ideas/idea-tr1-lmic-sites-in-pivotal-trials/)
- key papers: [DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer](https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/), [TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival](https://onco.cc/key-papers/paper-tropion-breast01-jco-2024/)

---
JSON: https://onco.cc/api/v1/entities/barrios-carlos.json